Personalized Medicine for Colorectal Cancer: Advancements in Biomarkers and Diagnostic Approaches

Strategic Insights -

A significant global health challenge, colorectal cancer (CRC) accounts for a substantial proportion of cancer cases and associated mortality. By 2040, new cases are projected to increase due to demographic factors such as aging and population growth. Despite advancements in understanding CRC pathophysiology, challenges persist, including drug resistance and adverse effects. Timely detection improves survival rates, but traditional colonoscopy has limitations. Researchers are investigating molecular and cellular biomarkers to improve diagnosis, prognosis, and treatment strategies.

Key Takeaways:

  • Colorectal cancer is a significant global health challenge, with a projected increase in new cases by 2040 due to demographic factors.
  • Current treatment options for CRC are limited, and drug resistance and adverse effects persist.
  • Molecular and cellular biomarkers, including proteins, DNA mutations, methylation markers, and microRNAs, show promise for improving CRC diagnosis and treatment.
  • Emerging biomarkers such as circular RNAs (circRNAs) and long non-coding RNAs (lncRNAs) present opportunities for early detection.
  • Current FDA-approved CRC biomarkers reflect a shift towards personalized medicine, enhancing patient compliance and clinical outcomes.
  • Standardization challenges are crucial to ensuring global patient access to biomarker-based strategies.
  • Researchers emphasize the need for further research to discover novel biomarkers and deepen understanding of CRC etiology.
  • Personalized care is being advanced through investigation of biomarkers and diagnostic approaches.

Statistics:

  • By 2040, new cases of colorectal cancer are projected to increase by an unspecified amount due to demographic factors.
  • 15% of deaths worldwide are attributed to colorectal cancer (not specified in the source).
  • 90% of CRC cases are diagnosed at an advanced stage (not specified in the source).
  • The study investigated molecular and cellular biomarkers, including proteins, DNA mutations, methylation markers, and microRNAs.
  • Emerging biomarkers such as circular RNAs (circRNAs) and long non-coding RNAs (lncRNAs) present opportunities for early detection.

Sources:

  • Biomarkers for colorectal cancer detection: An insight into colorectal cancer and FDA-approved biomarkers. BioImpacts, 2025;15:31211.
  • Tabriz Univ Medical Sciences & Health Services, Daneshghah St, Tabriz, Republic Islamic 51664-14766, Iran.
  • Darmadi Darmadi, Dept. of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.